• 1
    Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 6990.
  • 2
    Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 2011; 61: 183203.
  • 3
    Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 2011; 121: 3537.
  • 4
    Berek JS, Chalas E, Edelson M et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet. Gynecol. 2010; 116: 73343.
  • 5
    Tarn AC, Lapworth R. Biochemical analysis of ascitic (peritoneal) fluid: what should we measure? Ann. Clin. Biochem. 2010; 47: 397407.
  • 6
    Bielsa S, Porcel JM, Castellote J et al. Solving the Light's criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012; 17: 7216.
  • 7
    Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr. Opin. Oncol. 2010; 22: 4927.
  • 8
    Escudero JM, Auge JM, Filella X et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin. Chem. 2011; 57: 153444.
  • 9
    Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol. Oncol. 2002; 87: 7783.
  • 10
    Hernández P, Bielsa S, Pardina M et al. Meig's syndrome. Int. Pleural Newsl. 2011; 9: 10.
  • 11
    Maeda H, Okabayashi T, Hanazaki K et al. Clinical experience of pseudo-Meig's syndrome due to colon cancer. World J. Gastroenterol. 2011; 17: 32636.
  • 12
    Cetin B, Aslan S, Akinci M et al. A long survival case of pseudo-Meig's syndrome caused by Krukenberg tumor of the stomach. Jpn J. Clin. Oncol. 2005; 35: 2213.
  • 13
    Kawakubo N, Okido M, Tanaka R et al. Pseudo-Meig's syndrome associated with breast cancer metastasis to both ovaries: report of a case. Surg. Today 2010; 40: 114851.
  • 14
    Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch. Pathol. Lab. Med. 2006; 130: 172530.
  • 15
    Cellerin L, Marcq M, Sagan C et al. Pleurésies malignes révélatrices d'un cancer: comparaison des etiologies avec les pleurésies métastatiques d'un cancer connu. Rev. Mal. Respir. 2008; 25: 11049.
  • 16
    Wimberger P, Wehling M, Lehmann N et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann. Surg. Oncol. 2010; 17: 16428.
  • 17
    Bristow R, Amstrong D (eds). Ovarian Cancer. Saunders Elsevier, Philadelphia, PA, 2010.
  • 18
    Terauchi F, Kobayashi I, Nagashima T et al. Pilot study on transdiaphragmatic thoracoscopic assisted pleural biopsy and intrathoracic washing cytology for stage IIIc ovarian cancer with diaphragmatic metastases. Int. J. Gynecol. Cancer 2009; 19: 3003.
  • 19
    Fleury AC, Kushnir CL, Giuntoli IIRL et al. Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment. BJOG 2012; 119: 2026.
  • 20
    Porcel J, Rodríguez-Panadero F. Malignant effusions. In: Maskell N, Millar A (eds) Oxford Desk Reference: Respiratory Medicine. Oxford University Press, Oxford, 2009; 3425.
  • 21
    Rodríguez-Panadero F. Medical thoracoscopy. Respiration 2008; 76: 36372.
  • 22
    Ganjei-Azar P, Jordà M, Krishan A (eds). Effusion Cytology. A Practical Guide to Cancer Diagnosis. Demos Medical, New York, 2011.
  • 23
    Westfall DE, Fan X, Marchevsky AN. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn. Cytopathol. 2010; 38: 914.
  • 24
    Díaz JP, Abu-Rustum NR, Sonoda Y et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol. Oncol. 2010; 116: 4838.
  • 25
    Kim KW, Choi HJ, Kang S et al. The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur. J. Radiol. 2010; 75: 2305.
  • 26
    Mironov O, Sala E, Mironov S et al. Thoracic metastases in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery. J. Gynecol. Oncol. 2011; 22: 2608.
  • 27
    Cohen-Mouly S, Badia A, Bats AS et al. Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int. J. Gynecol. Cancer 2009; 19: 16625.
  • 28
    Juretzka MM, Abu-Rustum NR, Sonoda Y et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol. Oncol. 2007; 104: 6704.
  • 29
    Morgan RJ, Alvarez RD, Armstrong DK et al. Epithelial ovarian cancer. J. Natl Compr. Canc. Netw. 2011; 9: 82113.
  • 30
    Vergote I, Tropé CG, Amant F et al. Neodjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010; 363: 94353.
  • 31
    Amstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006; 354: 3443.
  • 32
    Chi DS, Eisenhauer EL, Zivanovic O et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 2009; 114: 2631.
  • 33
    Rauh-Hain JA, Rodriguez N, Growdon WB et al. Primary debulking surgery versus neodjuvant chemotherapy in stage IV ovarian carcinoma. Ann. Surg. Oncol. 2012; 19: 95965.
  • 34
    Gerestein CG, Eijkemans MJ, Bakker J et al. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. Anticancer Res. 2011; 31: 40439.
  • 35
    Aletti GD, Eisenhauer EL, Santillan A et al. Identification of patient groups at higher risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 2011; 120: 238.
  • 36
    Elattar A, Bryant A, Winter-Roach BA et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev. 2011; (8): CD007565.
  • 37
    Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20: 124859.
  • 38
    Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: Quo Vadis? Oncology (Williston Park) 2011; 25: 92834.
  • 39
    Eisenhauer EL, D'Angelica MI, Abu-Rustum NR et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol. Oncol. 2006; 103: 8717.
  • 40
    Gouy S, Chereau E, Custodio AS et al. Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer. J. Am. Coll. Surg. 2010; 210: 50914.
  • 41
    Fanfani F, Fagotti A, Gallotta V et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol. Oncol. 2010; 116: 497501.
  • 42
    Tsolakidis D, Amant F, Leunen K et al. Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients. Eur. J. Cancer 2011; 47: 1918.
  • 43
    Zapardiel I, Peiretti M, Zanagnolo V et al. Diaphragmatic surgery during primary cytoreduction for advanced ovarian cancer. Peritoneal stripping versus diaphragmatic resection. Int. J. Gynecol. Cancer 2011; 21: 1698703.
  • 44
    Chéreau E, Rouzier R, Gouy S et al. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. Eur. J. Surg. Oncol. 2011; 37: 17580.
  • 45
    Aletti GD, Podratz KC, Cliby WA et al. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol. Oncol. 2009; 112: 227.
  • 46
    Eisenkop SM. Thoracoscopy for the management of advanced epithelial ovarian cancer—A preliminary report. Gynecol. Oncol. 2002; 84: 31520.
  • 47
    Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011; 365: 247383.
  • 48
    Barbetakis N, Asteriou C, Papadopoulou F et al. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J. Cardiothorac. Surg. 2010; 5: 27.
  • 49
    Whitworth JM, Schneider KE, Fauci JM et al. Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion. Gynecol. Oncol. 2012
  • 50
    Bielsa S, Hernández P, Rodriguez-Panadero F et al. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung 2011; 189: 1515.
  • 51
    Lombardi G, Nicoletto MO, Gusella M et al. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother. Pharmacol. 2012; 69: 7817.
  • 52
    Marom EM, Erasmus JJ, Herndon JE et al. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. AJR Am. J. Roentgenol. 2002; 179: 1058.
  • 53
    Gross JL, DiSanzio TG, Younes RN et al. Do concomitant ascites influence the effectiveness of palliative surgical management of pleural effusions in patients with malignancies? World J. Surg. 2009; 33: 26671.
  • 54
    Eitan R, Levine DA, Abu-Rustum N et al. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 2005; 103: 1397401.
  • 55
    Mironov O, Ishill NM, Mironov S et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology 2011; 258: 77684.